Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
Status:
Completed
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The incidence is
highest in Asia and it is increasing in North America, with a two to three fold increase in
mortality in North America expected over the next two decades. Previous research has shown
that tumours often have abnormal blood vessels that may reduce the effect of radiation
therapy. New drugs, known as "anti-angiogenic" drugs have been shown in animal and human
studies to damage or change tumour blood vessels in ways that may make tumors more sensitive
to radiation treatment. 38-44 patients diagnosed with HCC will be invited to take part in
this study. Upon completion, this study will establish the safety of the combination of
radiation and sorafenib in patients with HCC. This will also establish preliminary data
regarding efficacy of the combination and investigate potential imaging and serum/tissue
markers surrogates for tumor response and/or drug activity.